drugset / Trial / NCT01307033

A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)

NCT01307033

Phase 3 Completed 278 enrolled Organon and Co
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is being conducted to evaluate the safety of MK-0954A (L100/H12.5 mg) in essential hypertension participants who are uncontrolled with MK-954H (L50/H12.5 mg).

Timeline

Start
2011-03-29
Primary completion
2012-12-04
Completion
2012-12-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Losartan Other / unclassified 50 mg Oral
Subject Losartan Other / unclassified 100 mg Oral
Background Hydrochlorothiazide Unknown 12.5 mg Oral

Indications